Journal Logo

Most Popular Articles

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Vera Aguilera, Jesus; Paludo, Jonas; McWilliams, Robert R.; More

Melanoma Research. 30(4):364-375, August 2020.

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Bisschop, Cornelis; ter Elst, Arja; Bosman, Lisette J.; More

Melanoma Research. 28(2):96-104, April 2018.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

Hodi, F. Stephen; Chapman, Paul B.; Sznol, Mario; More

Melanoma Research. 31(1):67-75, February 2021.

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis

Ziegler, Johanna S.; Kroeze, Stephanie; Hilbers, Marie-Luise; More

Melanoma Research. 30(6):552-561, December 2020.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Ascierto, Paolo A.; Bastholt, Lars; Ferrucci, Pier F.; More

Melanoma Research. 28(4):333-340, August 2018.

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Holtkamp, Lodewijka H.J.; Chakera, Annette H.; Fung, Sebastian; More

Melanoma Research. 30(4):358-363, August 2020.

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Bao, Riyue; Surriga, Oliver; Olson, Daniel J.; More

Melanoma Research. 31(1):27-37, February 2021.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Hintzsche, Jennifer D.; Gorden, Nicholas T.; Amato, Carol M.; More

Melanoma Research. 27(3):189-199, June 2017.

A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma

Mattei, Jane; Ballhausen, Alexej; Bassett, Roland; More

Melanoma Research. 30(6):574-579, December 2020.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma

Tarhini, Ahmad; Ghate, Sameer R.; Ionescu-Ittu, Raluca; More

Melanoma Research. 28(6):618-628, December 2018.

Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)

Moschos, Stergios J.; Eroglu, Zeynep; Khushalani, Nikhil I.; More

Melanoma Research. 31(2):162-172, April 2021.

Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models

Lobos-Gonzalez, Lorena; Aguilar-Guzmán, Lorena; Fernandez, Jaime G.; More

Melanoma Research. 24(2):108-119, April 2014.

Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma

de Haan, Jorine; Lok, Christianne A.; de Groot, Christianne J.; More

Melanoma Research. 27(3):218-223, June 2017.

Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Ismail, Rawa K.; Sikkes, Nienke O.; Wouters, Michel W.J.M.; More

Melanoma Research. 31(1):58-66, February 2021.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Drago, Joshua Z.; Lawrence, Donald; Livingstone, Elisabeth; More

Melanoma Research. 29(1):65-69, February 2019.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Mangana, Joanna; Cheng, Phil F.; Kaufmann, Corina; More

Melanoma Research. 27(4):358-368, August 2017.

Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec

Audrey-Bayan, Claire; Trager, Megan H.; Gartrell-Corrado, Robyn D.; More

Melanoma Research. 30(4):410-415, August 2020.

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

Vidarsdottir, Linda; Fernandes, Rita Valador; Zachariadis, Vasilios; More

Melanoma Research. 30(5):443-454, October 2020.

Show: